Navigation Links
New hope in fight against multi-resistant germs
Date:2/13/2013

This press release is available in German.

An increasing number of bacteria is evolving antibiotic resistance. Much-feared representatives of this steadily growing group include Staphylococci strains. At this point, multi-resistant forms of the bacterium Staphylococcus aureus - the "hospital germ" known commonly by its acronym, MRSA - can only be treated with a select subset of antibiotics as many drugs have simply stopped working. This is precisely why the field of medicine is in desperate need of new treatment options.

One highly promising drug candidate is now scheduled for testing in clinical trials. The substance, developed by the British pharmaceutical company GlaxoSmithKline, is still known by its rather cryptic working name, GSK1322322. In the course of clinical trials to evaluate new drugs, physicians typically end up with large numbers of patient samples that are invaluable in studying the different diseases patients are suffering from - samples that have, until recently, rarely been recruited for research purposes. Now, scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany, and at the TWINCORE Centre for Experimental and Clinical Infection Research in Hannover, Germany, aim to study such patient samples for a five-year-period. Part of a special collection at the Hannover Medical School's biobank, the samples will allow researchers to find out more about the etiology, course, and characteristic marker substances of infectious diseases. IMI, the Innovative Medicines Initiative, has awarded the scientists research grants totaling 6 million Euros as part of the COMBACTE (Combating Bacterial Resistance in Europe) project. IMI is a joint initiative by the European Union and the pharmaceutical industry. Dr. Frank Pessler, who heads TWINCORE's "Biomarkers in Infectious Diseases" research group, secured the grant and is the project's coordinator at HZI. Under his helmage, the scientists, along with their colleagues in Paris, Barcelona, and Philadelphia, will be searching for biomarkers - molecules that are unique to a particular disease and which may provide information about if the diagnosis was correct and whether or not the therapy is working.

The new antibiotic, GSK1322322, targets gram-positive bacteria including methicillin-resistant strains of Staphylococcus aureus - notorious MRSA - capable of causing serious skin and wound infections. Gram-positive germs are also frequently the culprit behind pneumonia. The drug targets the bacterial enzyme peptide deformylase. Phase I clinical trials, designed to evaluate a new drug's tolerability and safety profile, have already successfully concluded and showed only minor adverse effects. If the next study shows that GSK1322322 does not bestow any added benefit compared to current treatments, it will not be admitted into the next round of clinical trials. "This is where COMBACTE's added scientific value comes into play. In case this happens, the samples that were obtained will still offer insights into the infections they were supposed to treat, and perhaps aid in developing other better treatments" Frank Pessler explains.

Besides Pessler's own group, research teams headed by Prof. Susanne Hussler, Prof. Singh Chhatwal, Prof. Dietmar Pieper, Dr. Eva Medina, Prof. Irene Wagner-Dbler, Dr. Robert Geffers and Prof. Frank Klawonn are also involved in the project. Each team contributes its own special know-how, and, in concert, they are an excellent force. Adds Pessler: "Where else do you find this many experts from all these different disciplines under one roof, some of them even on the same floor? It makes the whole collaboration smooth and efficient."


'/>"/>

Contact: Jan Grabowski
jan.grabowski@helmholtz-hzi.de
49-531-618-11407
Helmholtz Centre for Infection Research
Source:Eurekalert  

Related medicine news :

1. WeightLossApp.com: The Skinny: Fighting Obesity in the Workplace Through an Innovative Mobile Application
2. Tiger Schulmann's MMA Student, Uriah Hall, Debuts on The Ultimate Fighter
3. Scientists Explore How Zinc Fights Off Infection
4. Electrical Brain Stimulation Plus Drug Fights Depression: Study
5. Tree-Savers™ Reports Successful Launch of Private St Beetle Lab; 100,000 Predator Beetles Now Available to Fight HWA Infestation
6. Scientists identify new strategy to fight deadly infection in cystic fibrosis
7. Bacterial supplement could help young pigs fight disease
8. Bioethics leader calls for bold approach to fighting obesity
9. Voices Against Brain Cancer Responds to a Mother’s Successful Fight Against her Glioblastoma
10. Vaccines Might Become Another Way to Fight Cancer
11. New American Chemical Society podcast: Leaves of carob tree fight food-poisoning bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New hope in fight against multi-resistant germs
(Date:1/23/2017)... ... ... Mill”: a story of love and redemption, hope and uncertainty as a girl makes ... “The Inn at the Mill” is the creation of published author, Lois Kulp, who was ... in Berks County on Crow Hill. The inn, the mill and "Post Yokel" ...
(Date:1/23/2017)... ... ... “Some Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring the ... of published author, Rev. Dr. Robert W. Thomas, the third of seven siblings. He ... nineteen, a pastor for over fifteen years. He is a graduate of N.C. College ...
(Date:1/22/2017)... ... January 22, 2017 , ... "Photo Cloud allows FCPX users to add ... slideshow with complete ease," said Christina Austin - CEO of Pixel Film Studios. ... FCPX timeline. Presets include scenes with one, three, four or five focus ...
(Date:1/21/2017)... ... ... is the perfect set of tools for video editors that want to create the illusion ... - CEO of Pixel Film Studios. , Video editors using ProDOF can add realistic ... racking focus from one area into the next. ProDOF comes with 0.5 second, 1.0 ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California ... has recently joined their multi-specialty medical group. The dermatology practice provides general dermatologic ... “We’re excited to add this excellent dermatology practice to our group’s medical services,” ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Stock-Callers.com today presents the following Generic ... CPRX ), Sophiris Bio Inc. (NASDAQ: SPHS ), ... Therapeutics Inc. (NASDAQ: AGRX ). These companies are ... late trade on Friday, January 20 th , 2017, with ... of health care companies in the S&P 500 also were ...
(Date:1/23/2017)... -- ResMed (NYSE : RMD), BMC (Pékin, Chine) et 3B Medical ... se sont mis d,accord sur le règlement mondial de ... 3B seront autorisés à vendre leurs produits existants en ... effectuera le paiement de la décision en une seule ... entre les deux parties. Le règlement n,inclut pas l,admission ...
(Date:1/23/2017)... Jan 23, 2017 InDex Pharmaceuticals Holding AB ... the 12th congress of the European Crohn,s and Colitis Organisation (ECCO). ... a specific focus on inflammatory bowel disease (IBD). The congress is ... 2017. ... are pleased to again having been selected to present data at ...
Breaking Medicine Technology: